Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 25 2018 - 11:29AM
Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company
focused on developing novel oncology and hematology therapeutics,
today announced that management will be presenting at the Ladenburg
Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at
9:00 a.m. ET in Track 3, St. Germain II Ballroom in the Sofitel New
York, New York City.
A live audio webcast of the presentation can be
accessed at www.aptevotherapeutics.com under the ‘Investors’
section of the website, under ‘Events.’ An audio reply of the
webcast will be available following the live webcast.
About Aptevo Therapeutics
Inc.Aptevo Therapeutics Inc. is a clinical-stage
biotechnology company focused on novel oncology and hematology
therapeutics to meaningfully improve patients’ lives. Aptevo
has a commercial product, IXINITY® coagulation factor IX
(recombinant), approved and marketed in the United States for the
treatment of Hemophilia B, and a versatile core technology – the
ADAPTIR™ modular protein technology platform capable of generating
highly-differentiated bispecific antibodies with unique mechanisms
of action to treat cancer or autoimmune diseases. Aptevo has
two ADAPTIR antibody candidates currently in clinical development
and a broad pipeline of novel investigational-stage bispecific
antibody candidates focused in immuno-oncology and autoimmune
disease and inflammation. For more information, please visit
www.aptevotherapeutics.com.
Source: Aptevo Therapeutics
Stacey JurchisonSenior Director, Investor Relations and Corporate
Communications206-859-6628 JurchisonS@apvo.com
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Sep 2023 to Sep 2024